A carregar...
Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
BACKGROUND AND AIMS: To investigate effectiveness and safety of teriflunomide (14 mg once daily) in association with age and pre-treatment in unselected MS patients. METHODS: Prespecified analysis of a non-interventional, prospective, real-world study in Germany. RESULTS: A total of 558 (49.5%) pati...
Na minha lista:
| Publicado no: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8135216/ https://ncbi.nlm.nih.gov/pubmed/34046085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562864211005588 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|